Ketamine In The Era Of Neurobiology
You may also be interested in...
Research has now revealed the mechanism underlying the anesthetic ketamine's rapid and sustained antidepressant effect: it activates an important signaling pathway in the prefrontal cortex of the brain. The findings provide clues that could lead to faster-acting drugs for depression or potentially even the adoption of current drugs for this use or augmentation of the effects of existing antidepressants.
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.